ClinicalTrials.gg
CompletedNCT03586830Updated Jan 7, 2020Results posted

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

A Phase 2 interventional study of JNJ-64565111 Dose Level 1 and JNJ-64565111 Dose Level 2 in Obesity and Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development, LLC. Completed at 27 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-01-07.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Obesity by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Obesity · Johnson & Johnson.

Enrollment
14th of 31
196 · median 113
Started
2018
with 2 others
Phase 2
10 of 35
none open now
Registered
33rd of 35
by date

Among the 35 studies in Obesity by Johnson & Johnson, this one is the 14th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 in phase 2, and was the 33rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 35 studies in Obesity by Johnson & Johnson is open now. The open studies under Obesity, anywhere →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Obesity by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from baseline and safety and tolerability.

03

Conditions studied

  • Obesity and Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) greater than or equal to (>=) 35 to less than or equal to (\<=) 50 kilogram per meter square (kg/m\^2) at screening
  • Stable weight (that is, change of \<= 5 percent [%] within 12 weeks before screening based on medical or participant reported history)
  • of >= 6.5% and \<= 9.5% at screening and meets one of the inclusion criteria as: (a) on diet and exercise alone >= 12 weeks prior to screening; (b) on stable dose of single oral antihyperglycemic agent (AHA) or dual-combination oral AHAs for >= 12 weeks prior to screening
  • Women must be either: (a) , or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of , or (d) Not heterosexually active
  • Willing and able to adhere to specific the prohibitions and restrictions

Exclusion criteria

Exclusion Criteria:

  • History of obesity with a known secondary cause (example, Cushing's disease/syndrome)
  • History of Type 1 diabetes mellitus, diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • Fasting C-peptide less than (\<) 0.7 nanogram per milliliter (ng/mL) at screening
  • Fasting fingerstick glucose of >= 270 milligram per deciliter (mg/dL) (>=15 millimoles per liter [mmol/L]) on Day 1
  • Ongoing, inadequately controlled thyroid disorder as assessed by the investigator's review of the participant's medical history. Participants taking thyroid hormone replacement therapy must be on stable doses for at least 6 weeks before the screening visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    JNJ-64565111 Dose Level 1

    Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.

    Drug: JNJ-64565111 Dose Level 1

  • Experimental
    JNJ-64565111 Dose Level 2

    Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.

    Drug: JNJ-64565111 Dose Level 2

  • Experimental
    JNJ-64565111 Dose Level 3

    Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.

    Drug: JNJ-64565111 Dose Level 3

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.

    Drug: Placebo

Interventions

  • Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.

  • Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.

  • Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.

  • DrugPlacebo

    Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 12

    Percent change from baseline in body weight in kilograms (kg) at Week 12 was reported.

    Time frame: Baseline, Week 12

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. An TEAE is defined as an AE with an onset after the initiation study medication and before the last study medication date of the double-blind (12-Week) treatment phase plus 35 Days.

    Time frame: Up to 16 Weeks

Secondary outcomes

  1. Change From Baseline in Body Weight at Week 12

    Change from baseline in body weight at Week 12 was reported.

    Time frame: Baseline, Week 12

  2. Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12

    Number of participants with \>= 5 % weight loss at Week 12 was reported.

    Time frame: Week 12

07

Results

Posted Jan 7, 2020

Participant flow

Participant flow — Overall Study
MilestonePlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
Started50484949
Treated49484949
Completed48424144
Not completed2685
Withdrew: Site terminated by sponsor1433
Withdrew: Lost to follow-up0221
Withdrew: Withdrawal by subject1031

Outcome measures

PrimaryPercent Change From Baseline in Body Weight at Week 12

Percent change from baseline in body weight in kilograms (kg) at Week 12 was reported.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Body Weight at Week 12
Percent ChangePlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
Percent Change From Baseline in Body Weight at Week 12-0.70 ± 0.50-5.25 ± 0.57-6.55 ± 0.56-7.92 ± 0.55
Statistical analysis
  • Placebo vs JNJ-64565111 5.0 mg · Hochberg Approach · p = <.001 · Difference of least square (ls) means: -4.56 · 95% CI -6.05 to -3.06
  • Placebo vs JNJ-64565111 7.4 mg · Hochberg Approach · p = <.001 · Difference of ls means: -5.85 · 95% CI -7.34 to -4.36
  • Placebo vs JNJ-64565111 10.0 mg · Hochberg Approach · p = <.001 · Difference of ls means: -7.23 · 95% CI -8.70 to -5.75
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. An TEAE is defined as an AE with an onset after the initiation study medication and before the last study medication date of the double-blind (12-Week) treatment phase plus 35 Days.

Time frame:
Up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs)28303936
SecondaryChange From Baseline in Body Weight at Week 12

Change from baseline in body weight at Week 12 was reported.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 12
kgPlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
Change From Baseline in Body Weight at Week 12-0.90 ± 0.577-5.92 ± 0.653-7.34 ± 0.648-9.04 ± 0.635
SecondaryNumber of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12

Number of participants with \>= 5 % weight loss at Week 12 was reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12
ParticipantsPlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 121202030

Adverse events

Collected over Up to 16 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/49 (0%)1/49 (2%)18/49 (36.7%)
JNJ-64565111 5.0 mg0/48 (0%)2/48 (4.2%)25/48 (52.1%)
JNJ-64565111 7.4 mg0/49 (0%)1/49 (2%)33/49 (67.3%)
JNJ-64565111 10.0 mg0/49 (0%)3/49 (6.1%)30/49 (61.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
ObesityMetabolism and nutrition disorders0/491/480/490/49
OsteoarthritisMusculoskeletal and connective tissue disorders0/491/480/490/49
BradycardiaCardiac disorders0/490/481/490/49
Gastroenteritis ViralInfections and infestations0/490/480/491/49
Incarcerated Incisional HerniaInjury, poisoning and procedural complications0/490/480/491/49
HyponatraemiaMetabolism and nutrition disorders0/490/480/491/49
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/490/480/490/49
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mg
NauseaGastrointestinal disorders5/4913/4817/4921/49
VomitingGastrointestinal disorders0/498/4812/4917/49
ConstipationGastrointestinal disorders2/494/489/494/49
Decreased AppetiteMetabolism and nutrition disorders2/495/487/497/49
DiarrhoeaGastrointestinal disorders2/493/482/496/49
Lipase IncreasedInvestigations2/492/483/496/49
Amylase IncreasedInvestigations2/492/485/493/49
Abdominal DistensionGastrointestinal disorders3/492/480/494/49
FatigueGeneral disorders1/491/484/491/49
Pancreatic Enzymes IncreasedInvestigations0/491/484/490/49

Baseline characteristics

Safety analysis set included all randomized participants who had received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mgTotal
Mean57.4 ± 9.0955.1 ± 9.5657.8 ± 8.9756.2 ± 8.5756.6 ± 9.04
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mgTotal
Female30322828118
Male1916212177
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mgTotal
Hispanic or Latino1012141551
Not Hispanic or Latino39363534144
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mgTotal
American Indian or Alaska Native00101
Asian10113
Native Hawaiian or Other Pacific Islander00000
Black or African American1210131752
White36383431139
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)PlaceboJNJ-64565111 5.0 mgJNJ-64565111 7.4 mgJNJ-64565111 10.0 mgTotal
UNITED STATES49484949195
08

Study locations

27 sites
  • Central Research Associates, Inc.
    Birmingham, Alabama 35205, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Rancho Cucamonga Clinical Trials
    Rancho Cucamonga, California 91730, United States
  • Sierra Clinical Research
    Roseville, California 95661, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Premeir Clinical Research Institute
    Miami, Florida 33122, United States
  • International Research Associates, LLC
    Miami, Florida 33183, United States
  • CNS HealthCare
    Orlando, Florida 32801, United States
  • Translational Research Institute for Metabolism and Diabetes
    Orlando, Florida 32804, United States
  • Buynak Clinical Research
    Valparaiso, Indiana 46383, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • M.D. Medical Research
    Oxon Hill, Maryland 20745, United States
  • AAMRC
    Flint, Michigan 48504, United States
  • Alas Science Clinical Research
    Henderson, Nevada 89014, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Albert J. Weisbrot and Associates
    Mason, Ohio 45040, United States
  • Clinical Research Institute of Southern Oregon, P.C.
    Medford, Oregon 97504, United States
  • Clinical Research Associates of Central PA, LLC
    Altoona, Pennsylvania 16602, United States
  • Heritage Valley Medical Group
    Beaver, Pennsylvania 15009, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • Dallas Diabetes & Endocrine Center at Medical City
    Dallas, Texas 75230, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • Permian Research Foundation
    Odessa, Texas 79761, United States
  • Spectrum Medical, Inc
    Danville, Virginia 24541, United States
  • Dominion Medical Associates, Inc.
    Richmond, Virginia 23219, United States
  • National Clinical Research
    Richmond, Virginia 23294, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Apr 2019, 9 months.

Results were first posted in Jan 2020, 9 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2018
First posted
Jul 16, 2018
StartActual
Jun 26, 2018
Primary completionActual
Apr 5, 2019
CompletionActual
Apr 5, 2019
Results first posted
Jan 7, 2020
Last update
Jan 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03586830
Responsible party
Sponsor
First posted
Jul 16, 2018
Start date
Jun 26, 2018
Primary completion
Apr 5, 2019
Completion
Apr 5, 2019
Results posted
Jan 7, 2020
Last update
Jan 7, 2020

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion